Pulmatrix, Inc. (PULM) Stock

Pulmatrix, Inc. (PULM) is a Healthcare stock trading at $1.49 (as of 2026-08-21), with a market capitalization of $5.42M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Pulmatrix, Inc. develops inhaled therapies and related drug candidates for respiratory and other diseases, including Pulmazole, PUR1800, and PUR3100. The company’s work is based on its iSPERSE inhalation technology and it operates in the United States, conducting clinical development and collaborating through licensing and development agreements with other entities.

Understand Pulmatrix, Inc.: how it makes money

Pulmatrix develops inhaled therapies for respiratory and other diseases, using its inhaled small particles easily respirable and emitted (iSPERSE) technology to deliver drugs to the lungs by inhalation (both local and systemic).

As a clinical stage biotech, its value creation and potential future profits depend on whether its inhaled therapies (built on iSPERSE, including Pulmazole) successfully progress through development to regulatory and commercialization outcomes.

Business quality (Weak): Clear scientific focus (iSPERSE) and a defined development program (Pulmazole for allergic bronchopulmonary aspergillosis in asthma), but there is no demonstrated operating scale yet, and outcomes depend heavily on clinical and regulatory progress.

Bull case

  • Platform-based inhalation delivery: The company focuses on its iSPERSE technology, which it says can deliver small or large molecule drugs to the lungs by inhalation for local or systemic applications.
  • Defined lead product candidate: Pulmazole is being developed as an inhaled anti-fungal drug for allergic bronchopulmonary aspergillosis in patients with asthma.

Bear case

  • Clinical stage dependence: Because the company is clinical stage, progress and outcomes for inhaled therapies remain uncertain and are critical to any future ability to generate revenue.
  • No operating scale yet: In the latest reported period shown, revenue is 0.0B and operating margin is deeply negative, consistent with ongoing development costs without current revenue generation.
Valuation — source: SEC EDGAR (first-party)
Price$1.49
Market Cap$5.42M
Price / Book2.12
Price / Sales84.74
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$144000.00
Net Margin-3584.7%
Revenue Growth (YoY)-98.2%
EPS Growth (YoY)-46.2%
Financial Health — source: SEC EDGAR
Altman Z-Score-95.35 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRENAISSANCE TECHNOLOGIES LLC ($140801.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPeter Ludlum
Employees2
CountryUS
IPO Date2014-03-21

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Bolt Biotherapeutics, Inc. (BOLT)
  • Acurx Pharmaceuticals, Inc. (ACXP)
  • Enveric Biosciences, Inc. (ENVB)
  • Dermata Therapeutics, Inc. (DRMA)
  • Processa Pharmaceuticals, Inc. (PCSA)
  • Cadrenal Therapeutics, Inc. Common Stock (CVKD)
  • Lakewood-Amedex Biotherapeutics Inc. (LABT)
  • Aptevo Therapeutics Inc. (APVO)
PULM earnings history · PULM institutional & insider holders · PULM KPIs & operating metrics · PULM financials · PULM investor presentations & press releases · PULM SEC filings · PULM peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.